Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01044433 · OUTCOME

Progression-free Survival

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck · Source last updated 2020-03-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
months
Interval / dispersion
90% Confidence Interval
Time frame
5 years

Groups in this outcome

Arm I

Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. lapatinib ditosylate: Given orally capecitabine: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I44

Reported measurements

Source class 1
Values in months · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I4.2Not reported3.65.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.6
        upper Limit
        5.1
        value
        4.2
denoms
  1. counts
    1. group Id
      OG000
      value
      44
    units
    Participants
dispersion Type
90% Confidence Interval
groups
  1. description
    Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. lapatinib ditosylate: Given orally capecitabine: Given orally
    id
    OG000
    title
    Arm I
param Type
NUMBER
reporting Status
POSTED
time Frame
5 years
title
Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice